[1] Dumont N, Arteaga CL. Transforming growth factor-beta and breast cancer: Tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000; 2(2): 93
[https://doi.org/10.1186/bcr44]
[2] Karakosta A, Golias C, Charalabopoulos A, Peschos D, Batistatou A, Charalabopoulos K. Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J Exp Clin Cancer Res 2005; 24(4): 505–14
[PMID: 16471312]
[3] Ehrlich M. Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr Top Microbiol Immunol 2006; 310: 251–74
[PMID: 16909914]
[4] Ting AH, McGarvey KM, Baylin SB. The cancer epigenome--components and functional correlates. Genes Dev 2006; 20(23): 3215–31
[https://doi.org/10.1101/gad.1464906][PMID: 17158741]
[5] Chan TL, Yuen ST, Kong CK, et al. Heritable germline epimutation of MSH2 in a family with hereditary nonpolyposis colorectal cancer. Nat Genet 2006; 38(10): 1178–83
[https://doi.org/10.1038/ng1866][PMID: 16951683]
[6] Goel A, Nguyen T-P, Leung H-CE, et al. De novo constitutional MLH1 epimutations confer early-onset colorectal cancer in two new sporadic Lynch syndrome cases, with derivation of the epimutation on the paternal allele in one. Int J Cancer 2011; 128(4): 869–78
[https://doi.org/10.1002/ijc.25422][PMID: 20473912]
[7] Hansmann T, Pliushch G, Leubner M, et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet 2012; 21(21): 4669–79
[https://doi.org/10.1093/hmg/dds308][PMID: 22843497]
[8] Böck J, Appenzeller S, Haertle L, et al. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients. Int J Cancer 2018; 143(6): 1416–25
[https://doi.org/10.1002/ijc.31526][PMID: 29659014]
[9] Hitchins MP. Finding the needle in a haystack: identification of cases of Lynch syndrome with MLH1 epimutation. Fam Cancer 2016; 15(3): 413–22
[https://doi.org/10.1007/s10689-016-9887-3][PMID: 26886015]
[10] Ligtenberg MJL, Kuiper RP, Chan TL, et al. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet 2009; 41(1): 112–7
[https://doi.org/10.1038/ng.283][PMID: 19098912]
[11] Raval A, Tanner SM, Byrd JC, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell 2007; 129(5): 879–90
[https://doi.org/10.1016/j.cell.2007.03.043][PMID: 17540169]
[12] D'Orazio JA. Inherited cancer syndromes in children and young adults. J Pediatr Hematol Oncol 2010; 32(3): 195–228
[https://doi.org/10.1097/MPH.0b013e3181ced34c][PMID: 20186103]
[13] van Echten-Arends J, Mastenbroek S, Sikkema-Raddatz B, et al. Chromosomal mosaicism in human preimplantation embryos: a systematic review. Hum Reprod Update 2011; 17(5): 620–7
[https://doi.org/10.1093/humupd/dmr014][PMID: 21531753]
[14] Hafner C, Groesser L. Mosaic RASopathies. Cell Cycle 2013; 12(1): 43–50
[https://doi.org/10.4161/cc.23108][PMID: 23255105]
[15] Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011; 157C(2): 83–9
[https://doi.org/10.1002/ajmg.c.30300][PMID: 21500339]
[16] Walker CL, Ho S-m. Developmental reprogramming of cancer susceptibility. Nat Rev Cancer 2012; 12(7): 479–86
[https://doi.org/10.1038/nrc3220][PMID: 22695395]
[17] Marshall GM, Carter DR, Cheung BB, et al. The prenatal origins of cancer. Nat Rev Cancer 2014; 14(4): 277–89
[https://doi.org/10.1038/nrc3679][PMID: 24599217]
[18] Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: Identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997; 94(25): 13950–4
[PMID: 9391133]
[19] Hjalgrim LL, Madsen HO, Melbye M, et al. Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia. Br J Cancer 2002; 87(9): 994–9
[https://doi.org/10.1038/sj.bjc.6600601][PMID: 12434291]
[20] McHale CM, Wiemels JL, Zhang L, et al. Prenatal origin of childhood acute myeloid leukemias harboring chromosomal rearrangements t(15;17) and inv(16). Blood 2003; 101(11): 4640–1
[https://doi.org/10.1182/blood-2003-01-0313][PMID: 12756163]
[21] Hitzler JK, Zipursky A. Origins of leukaemia in children with Down syndrome. Nat Rev Cancer 2005; 5(1): 11–20
[https://doi.org/10.1038/nrc1525][PMID: 15630411]
[22] Bennett-Baker PE, Wilkowski J, Burke DT. Age-associated activation of epigenetically repressed genes in the mouse. Genetics 2003; 165(4): 2055–62
[PMID: 14704185]
[23] Galetzka D, Hansmann T, El Hajj N, et al. Monozygotic twins discordant for constitutive BRCA1 promoter methylation, childhood cancer and secondary cancer. Epigenetics 2012; 7(1): 47–54
[https://doi.org/10.4161/epi.7.1.18814][PMID: 22207351]
[24] Magnusson S, Borg A, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer 2008; 7(4): 331–7
[https://doi.org/10.1007/s10689-008-9195-7][PMID: 18481196]
[25] Sharma B, Preet Kaur R, Raut S, Munshi A. BRCA1 mutation spectrum, functions, and therapeutic strategies: The story so far. Curr Probl Cancer 2018; 42(2): 189–207
[https://doi.org/10.1016/j.currproblcancer.2018.01.001][PMID: 29452958]
[26] Sedic M, Skibinski A, Brown N, et al. Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 2015; 6: 7505
[https://doi.org/10.1038/ncomms8505][PMID: 26106036]
[27] Shim YH1 et al., 2000. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab Invest; 2000(May: 80(5)): 689–95.
[28] Esteller M, Fraga MF, Guo M, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10(26): 3001–7
[PMID: 11751682]
[29] Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18(22): 2699–711
[https://doi.org/10.1101/gad.1256504][PMID: 15545627]
[30] Nieuwenhuis MH, Vasen HFA. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007; 61(2): 153–61
[https://doi.org/10.1016/j.critrevonc.2006.07.004][PMID: 17064931]
[31] Bienz M, Hamada F. Adenomatous polyposis coli proteins and cell adhesion. Curr Opin Cell Biol 2004; 16(5): 528–35
[https://doi.org/10.1016/j.ceb.2004.08.001][PMID: 15363803]
[32] Caldwell CM, Kaplan KB. The role of APC in mitosis and in chromosome instability. Adv Exp Med Biol 2009; 656: 51–64
[PMID: 19928352]
[33] Kuang S-Q, Tong W-G, Yang H, et al. Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. Leukemia 2008; 22(8): 1529–38
[https://doi.org/10.1038/leu.2008.130][PMID: 18528427]
[34] Shi H, Guo J, Duff DJ, et al. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis 2007; 28(1): 60–70
[https://doi.org/10.1093/carcin/bgl092][PMID: 16774933]
[35] Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2(1): a001008
[https://doi.org/10.1101/cshperspect.a001008][PMID: 20182602]
[36] Shirole NH, Pal D, Kastenhuber ER, et al. TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions. Elife 2016; 5
[https://doi.org/10.7554/eLife.17929][PMID: 27759562]
[37] Lieberman HB, Bernstock JD, Broustas CG, Hopkins KM, Leloup C, Zhu A. The role of RAD9 in tumorigenesis. J Mol Cell Biol 2011; 3(1): 39–43
[https://doi.org/10.1093/jmcb/mjq039][PMID: 21278450]
[38] Cheng CK, Chow LWC, Loo WTY, Chan TK, Chan V. The cell cycle checkpoint gene Rad9 is a novel oncogene activated by 11q13 amplification and DNA methylation in breast cancer. Cancer Res 2005; 65(19): 8646–54
[https://doi.org/10.1158/0008-5472.CAN-04-4243][PMID: 16204032]
[39] Zhu A, Zhang CX, Lieberman HB. Rad9 has a functional role in human prostate carcinogenesis. Cancer Res 2008; 68(5): 1267–74
[https://doi.org/10.1158/0008-5472.CAN-07-2304][PMID: 18316588]
[40] Weis E, Schoen H, Victor A, et al. Reduced mRNA and protein expression of the genomic caretaker RAD9A in primary fibroblasts of individuals with childhood and independent second cancer. PLoS ONE 2011; 6(10): e25750
[https://doi.org/10.1371/journal.pone.0025750][PMID: 21991345]
[41] Magadier F, Billard Lise-Marie, Wittmann, Gaelle, Frappart Lucien, et al. Regional methylation of the 5′ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. The FASEB Journal 2000; 14(11): 1585–94
[https://doi.org/10.1096/fj.99-0817com]
[42] Weber M, Hellmann I, Stadler MB, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 2007; 39(4): 457–66
[https://doi.org/10.1038/ng1990][PMID: 17334365]
[43] Phipps SMO, Berletch JB, Andrews LG, Tollefsbol TO. Aging cell culture: methods and observations. Methods Mol Biol 2007; 371: 9–19
[https://doi.org/10.1007/978-1-59745-361-5_2][PMID: 17634570]
[44] Flunkert J, Maierhofer A, Dittrich M, et al. Genetic and epigenetic changes in clonal descendants of irradiated human fibroblasts. Exp Cell Res 2018; 370(2): 322–32
[https://doi.org/10.1016/j.yexcr.2018.06.034][PMID: 29964050]
[45] Maierhofer A, Flunkert J, Dittrich M, et al. Analysis of global DNA methylation changes in primary human fibroblasts in the early phase following X-ray irradiation. PLoS ONE 2017; 12(5): e0177442
[https://doi.org/10.1371/journal.pone.0177442][PMID: 28489894]
[46] Zunino F, Gambetta R, Di Marco A, Zaccara A. Interaction of daunomycin and its derivatives with DNA. Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis 1972; 277(3): 489–98
[https://doi.org/10.1016/0005-2787(72)90092-5]
[47] Peterson C, Trouet A. Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res 1978; 38(12): 4645–9
[PMID: 719643]
[48] Przybylska M, Koceva-Chyla A, Rózga B, Józwiak Z. Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity. Cell Biol Int 2001; 25(2): 157–70
[https://doi.org/10.1006/cbir.2000.0583][PMID: 11237420]
[49] Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 1986; 73(4): 320–6
[https://doi.org/10.1007/BF00279094]
[50] Hernandez-Vargas H, Gruffat H, Cros MP, et al. Viral driven epigenetic events alter the expression of cancer-related genes in Epstein-Barr-virus naturally infected Burkitt lymphoma cell lines. Sci Rep 2017; 7(1): 5852
[https://doi.org/10.1038/s41598-017-05713-2][PMID: 28724958]
[51] Davidson JM, Gorringe KL, Chin S-F, et al. Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer 2000; 83(10): 1309–17
[https://doi.org/10.1054/bjoc.2000.1458]
[52] Rangan S. A new human cell line (FaDu) from a hypopharyngeal carcinoma.
[53] Kytl S, Rummukainen J, Nordgren A, et al. Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosom. Cancer 2000; 28(3): 308–17
[https://doi.org/10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B]
[54] Amin NA, Seymour E, Saiya-Cork K, Parkin B, Shedden K, Malek SN. A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia. Clin Cancer Res 2016; 22(17): 4525–35
[https://doi.org/10.1158/1078-0432.CCR-15-3103][PMID: 27060156]
[55] Ben-David U, Siranosian B, Ha G, et al. Genetic and transcriptional evolution alters cancer cell line drug response. Nature 2018; 560(7718): 325–30
[https://doi.org/10.1038/s41586-018-0409-3][PMID: 30089904]
[56] Nichols AC, Yoo J, Palma DA, et al. Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines. Arch Otolaryngol Head Neck Surg 2012; 138(8): 732–9
[https://doi.org/10.1001/archoto.2012.1558][PMID: 22911296]
[57] Luijsterburg MS, Krijger I de, Wiegant WW, et al. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining. Mol Cell 2016; 61(4): 547–62
[https://doi.org/10.1016/j.molcel.2016.01.019][PMID: 26895424]
[58] Eckey M, Kuphal S, Straub T, et al. Nucleosome remodeler SNF2L suppresses cell proliferation and migration and attenuates Wnt signaling. Molecular and Cellular Biology 2012; 32(13): 2359–71
[https://doi.org/10.1128/MCB.06619-11][PMID: 22508985]
[59] Dimaras H, Khetan V, Halliday W, et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum Mol Genet 2008; 17(10): 1363–72
[https://doi.org/10.1093/hmg/ddn024][PMID: 18211953]
[60] Thériault BL, Dimaras H, Gallie BL, Corson TW. The genomic landscape of retinoblastoma: a review. Clin Experiment Ophthalmol 2014; 42(1): 33–52
[https://doi.org/10.1111/ceo.12132][PMID: 24433356]
[61] Rushlow DE, Mol BM, Kennett JY, et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. The Lancet Oncology 2013; 14(4): 327–34
[https://doi.org/10.1016/S1470-2045(13)70045-7]
[62] Broustas CG, Zhu A, Lieberman HB. Rad9 protein contributes to prostate tumor progression by promoting cell migration and anoikis resistance. J Biol Chem 2012; 287(49): 41324–33
[https://doi.org/10.1074/jbc.M112.402784][PMID: 23066031]
[63] Tsai F-L, Kai M. The checkpoint clamp protein Rad9 facilitates DNA-end resection and prevents alternative non-homologous end joining. Cell Cycle 2014; 13(21): 3460–4
[https://doi.org/10.4161/15384101.2014.958386][PMID: 25485590]
[64] Komatsu K, Miyashita T, Hang H, et al. Human homologue of S. pombe Rad9 interacts with BCL-2/BCL-xL and promotes apoptosis. Nat Cell Biol 2000; 2(1): 1–6
[https://doi.org/10.1038/71316][PMID: 10620799]
[65] Yoshida K, Komatsu K, Wang H-G, Kufe D. c-Abl Tyrosine Kinase Regulates the Human Rad9 Checkpoint Protein in Response to DNA Damage. Molecular and Cellular Biology 2002; 22(10): 3292–300
[https://doi.org/10.1128/MCB.22.10.3292-3300.2002]
[66] Horsthemke B. Epimutations in human disease. Curr Top Microbiol Immunol 2006; 310: 45–59
[PMID: 16909906]
[67] Tomasetti C, Li L, Vogelstein B. Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science 2017; 355(6331): 1330–4
[https://doi.org/10.1126/science.aaf9011][PMID: 28336671]
[68] Lopez-Lazaro M. The stem cell division theory of cancer. Crit Rev Oncol Hematol 2018; 123: 95–113
[https://doi.org/10.1016/j.critrevonc.2018.01.010][PMID: 29482784]
[69] Manuela Marron. Cancer in childhood and molecular epidemiology - The KIKME case-control study [abstract] 2017: 77 (13 Suppl): Abstract nr 4261. doi:10.1158/1538-7445.AM2017-4261.
[70] Victor A, Weis E, Messow CM, et al. Searching for gene expression differences in primary fibroblasts between patients with one and two neoplasms in childhood. Pediatr Hematol Oncol 2013; 30(1): 33–45
[https://doi.org/10.3109/08880018.2012.735747][PMID: 23140311]
[71] Weis E, Galetzka D, Herlyn H, Schneider E, Haaf T. Humans and chimpanzees differ in their cellular response to DNA damage and non-coding sequence elements of DNA repair-associated genes. Cytogenet Genome Res 2008; 122(2): 92–102
[https://doi.org/10.1159/000163086][PMID: 19096204]
[72] Menegakis A, Yaromina A, Eicheler W, et al. Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining. Int J Radiat Biol 2009; 85(11): 1032–41
[https://doi.org/10.3109/09553000903242149][PMID: 19895280]
[73] Rahmann S, Beygo J, Kanber D, Martin M, Horsthemke B, Buiting K. Amplikyzer: Automated methylation analysis of amplicons from bisulfite flowgram sequencing 2013.
[74] R Core Team (2015). R: A language and environment for statistical computing. Vienna, Austria. URL https://www.R-project.org/.
[75] Hughes S, Jones JL. The use of multiple displacement amplified DNA as a control for methylation specific PCR, pyrosequencing, bisulfite sequencing and methylation-sensitive restriction enzyme PCR. BMC Mol Biol 2007; 8: 91
[https://doi.org/10.1186/1471-2199-8-91][PMID: 17939862]
[76] Feng W, Shen L, Wen S, et al. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 2007; 9(4): R57
[https://doi.org/10.1186/bcr1762][PMID: 17764565]
[77] Schatz P, Distler J, Berlin K, Schuster M. Novel method for high throughput DNA methylation marker evaluation using PNA-probe library hybridization and MALDI-TOF detection. Nucleic Acids Res 2006; 34(8): e59
[https://doi.org/10.1093/nar/gkl218][PMID: 16670426]
[78] Flanagan JM, Popendikyte V, Pozdniakovaite N, et al. Intra- and Interindividual Epigenetic Variation in Human Germ Cells. Am J Hum Genet 2006; 79(1): 67–84
[PMID: 16773567]